Adjuvant Therapy for Ovarian Cancer with Radioactive Antibodies
Author Information
Author(s): V. Hirdl, A. Maraveyas, D. Snook, B. Dhokial, W.P. Soutter, C. Meares, J.S.W. Stewart, P. Mason, H.E. Lambert, A.A. Epenetos
Primary Institution: Imperial Cancer Research Fund Oncology Group, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London
Hypothesis
Can intraperitoneal radioactive monoclonal antibody therapy improve outcomes for patients with advanced ovarian cancer after conventional treatment?
Conclusion
The study suggests that patients with advanced ovarian cancer who achieve complete remission after conventional therapy may benefit from additional treatment with radioactive monoclonal antibodies.
Supporting Evidence
- 21 out of 52 patients had no evidence of residual disease after treatment.
- The treatment was well tolerated with only reversible myelosuppression observed.
- Survival data showed a difference in outcomes compared to historical controls.
Takeaway
Doctors gave a special treatment to 52 women with ovarian cancer after their regular treatment, and it seemed to help some of them stay healthier for longer.
Methodology
Patients received intraperitoneal radioimmunotherapy with yttrium-90-labelled monoclonal antibody HMFG1 after surgery and chemotherapy.
Potential Biases
The study included a mixture of cancer stages, which may affect the results.
Limitations
The study had a small number of patients and was not a randomized trial.
Participant Demographics
Patients' ages ranged from 29 to 76 years, all had performance status above WHO Grade 2.
Want to read the original?
Access the complete publication on the publisher's website